The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 450.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 20.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 450.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK and EU regulatory approval update

26 Feb 2024 07:00

RNS Number : 3374E
Tristel PLC
26 February 2024
 

TRISTEL plc

("Tristel", the "Company", or the "Group")

 

UK and EU regulatory approval update for surface disinfection system

 

Sustainable alternative to commonly used pre-wetted plastic wipes to become available in Europe

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that all reviews under the Medical Devices Regulation 2002 ("UK MDR") and the European Union Medical Device Regulation 2017/745 ("EU MDR") for approval of the Company's TANK ClO? Sporicidal Disinfectant system have been successfully concluded and a positive recommendation for UKCA and MDR certification has been made.

 

The TANK system and accompanying capsules are the newest additions to the Cache range, which provides sporicidal surface disinfection in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Following MDR approvals Tristel will be able to accelerate sales activity for this product throughout Europe and across geographies that recognise the high standard of safety and quality demonstrated by products conforming to the new EU MDR. The Directors believe that approval, will give Tristel the opportunity to deliver significant growth in sales of the Cache product range going forward, targeting a largely untapped sporicidal surface disinfection market. The Company expects to officially launch these latest products in Europe before the current financial year end on 30 June 2024.

 

For the year ended 30 June 2023 revenues from the Cache range totalled £3.3m, representing 9.2% of total annual turnover.

 

About TANK ClO? Sporicidal Disinfectant and the Cache range (https://thecachecollection.com)

TANK ClO? Sporicidal Disinfectant is a storage and distribution system powered by ClO? sporicidal disinfectant capsules. One TANK ClO? Sporicidal Disinfectant capsule makes 10 litres of sporicidal solution, which is the same as 2,000 sporicidal wipes wetted with 5ml of liquid. Rather than relying on convenience products that do harm once they are disposed of, TANK uses plastic thoughtfully. The core components are reusable, and all the plastic items within the system are recyclable. Users can apply TANK ClO? Sporicidal Disinfectant working solution with a Doser, Foamer or Sprayer, and reduce plastic waste by pairing TANK working solution with any dry wipe.

 

 

The TANK ClO? Sporicidal Disinfectant system

 

 

The broader Cache product range for sporicidal surface disinfection

 

For further information on the TANK ClO? Sporicidal Disinfectant system please view the product brochure here:

https://thecachecollection.com/wp-content/uploads/2021/09/Mkt-Bro-1508-6-TANK-ClO2-Sporicidal-Brochure-EN.pdf

 

Paul Swinney, CEO of Tristel, commented: "Whilst our Cache product range is intended for environmental surfaces, many of the surfaces in a hospital setting are considered medical devices and so it is key for any disinfection products to comply with the new EU Medical Device Regulation. It is a very significant achievement to have concluded all reviews successfully and we expect to receive our recommendation for certification from our Notified Body very shortly. Conformity with MDR will allow us to apply CE marking to these new products and gives us the opportunity to deliver significant growth in sales of the Cache product range going forward."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Charlotte Edgar

Mob: 07884 664 686

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGZGZZNFRGDZM
Date   Source Headline
24th Apr 20147:00 amRNSSuccess in controlling Clostridium difficile rates
13th Mar 20147:00 amRNSPublic Health England tackle disease threats
3rd Mar 20147:01 amRNSGrant of Share Options
3rd Mar 20147:00 amRNSHalf Yearly Report
13th Feb 20147:00 amRNSInvestor Results Presentation
22nd Jan 20147:00 amRNSTrading Update and notice of results
10th Dec 20132:14 pmRNSResult of AGM
10th Dec 20137:00 amRNSAGM Statement
15th Nov 20137:00 amRNSPosting of Annual Report & Notice of AGM
18th Oct 20137:00 amRNSPeer-reviewed published article
14th Oct 20137:00 amRNSFinal Results
22nd Jul 20137:00 amRNSTrading Update & Notice of Results
28th May 20132:19 pmRNSDirector/PDMR Shareholding
29th Apr 20132:53 pmRNSHolding(s) in Company
15th Apr 20131:47 pmRNSHolding(s) in Company
10th Apr 201311:45 amRNSHolding(s) in Company
9th Apr 201311:18 amRNSDirectors' Shareholdings
21st Mar 20132:44 pmRNSHolding(s) in Company
4th Mar 20139:28 amRNSDirector Shareholding
4th Mar 20137:00 amRNSHalf Yearly Report
14th Feb 20137:00 amRNSTrading update and notice of results
18th Jan 20137:00 amRNSTristel Wipes System obtains approval in China
17th Jan 20137:00 amRNSPeer-reviewed published articles
11th Dec 201212:56 pmRNSResult of AGM
29th Oct 20127:00 amRNSFinal Results
29th Aug 20127:00 amRNSDirector/PDMR Shareholding
8th Aug 20127:00 amRNSDirectorate Change
2nd Aug 20127:00 amRNSNew website
23rd Jul 201210:29 amRNSDirector/PDMR Shareholding
23rd Jul 20127:00 amRNSTrading update
9th Jul 20127:00 amRNSSupply&distribution agreement - Basan Germany GmbH
25th Jun 20127:00 amRNSDirectorate Change
15th Jun 201211:40 amRNSDirectors' Shareholdings
15th Jun 20127:00 amRNSTrading Update
12th Jun 20127:00 amRNSResult of Clinical Study
30th Apr 20129:00 amRNSDirectors' Dealings
3rd Apr 20127:00 amRNSTermination of supply arrangement
30th Mar 20127:00 amRNSResults of Clinical Study
12th Mar 20127:00 amRNSHalf Yearly Report
8th Mar 20127:00 amRNSNotice of Results
11th Jan 20123:17 pmRNSDirector/PDMR Shareholding
4th Jan 20128:50 amRNSDirector/PDMR Shareholding
23rd Dec 201112:16 pmRNSDirector/PDMR Shareholding
21st Dec 20113:40 pmRNSGrant of Share Options
13th Dec 201111:52 amRNSResult of AGM
8th Dec 20114:24 pmRNSDirector/PDMR Shareholding
25th Nov 20111:22 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSDirector's Dealing
11th Nov 201110:27 amRNSDirector/PDMR Shareholding
4th Nov 20112:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.